APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multivalent Influenza Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Multivalent Influenza Vaccines Market Analysis and Forecast 2026-2032

30 December 2025205 pages

Choose your research edition.

Industry ResearchMultivalent Influenza Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Multivalent Influenza Vaccines Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Multivalent Influenza Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multivalent Influenza Vaccines Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multivalent Influenza Vaccines Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Multivalent Influenza Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Multivalent Influenza Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Multivalent Influenza Vaccines include CSL, KM Biologics, Viatris, AstraZeneca, Bcht Biotechnology, Sinovac, Aleph Biomedical, GSK and ADIMMUNE Corporation, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Multivalent Influenza Vaccines, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Multivalent Influenza Vaccines, also provides the sales of main regions and countries. Of the upcoming market potential for Multivalent Influenza Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Multivalent Influenza Vaccines sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Multivalent Influenza Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Multivalent Influenza Vaccines sales, projected growth trends, production technology, application and end-user industry.

Multivalent Influenza Vaccines Segment by Company

CSL

KM Biologics

Viatris

AstraZeneca

Bcht Biotechnology

Sinovac

Aleph Biomedical

GSK

ADIMMUNE Corporation

Hualan Bio

Jiangsu GDK

Sanofi

Shanghai Institute of Biological Products

Wuhan Institute of Biological Products

Changchun Institute of Biological

Zhongyianke Biotech

Multivalent Influenza Vaccines Segment by Type

Quadrivalent Inactivated Influenza Vaccine (IIV4)

Trivalent Inactivated Influenza Vaccine (IIV3)

Trivalent Live Attenuated Vaccine (LAIV3)

Multivalent Influenza Vaccines Segment by Application

6 Months to 3 Years

Above 3 Years

Multivalent Influenza Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Influenza Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multivalent Influenza Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Influenza Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Multivalent Influenza Vaccines in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Multivalent Influenza Vaccines manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Multivalent Influenza Vaccines sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Multivalent Influenza Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Quadrivalent Inactivated Influenza Vaccine (IIV4) Major Manufacturers Table 3. Trivalent Inactivated Influenza Vaccine (IIV3) Major Manufacturers Table 4. Trivalent Live Attenuated Vaccine (LAIV3) Major Manufacturers Table 5. Global Multivalent Influenza Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. 6 Months to 3 Years Major Manufacturers Table 7. Above 3 Years Major Manufacturers Table 8. Multivalent Influenza Vaccines Industry Trends Table 9. Multivalent Influenza Vaccines Industry Drivers Table 10. Multivalent Influenza Vaccines Industry Opportunities and Challenges Table 11. Multivalent Influenza Vaccines Industry Restraints Table 12. Global Multivalent Influenza Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Multivalent Influenza Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Multivalent Influenza Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2021-2026) Table 16. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2027-2032) Table 17. Global Multivalent Influenza Vaccines Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Multivalent Influenza Vaccines Sales by Region (2021-2026) & (K Units) Table 19. Global Multivalent Influenza Vaccines Sales by Region (2027-2032) & (K Units) Table 20. Global Multivalent Influenza Vaccines Sales Market Share by Region (2021-2026) Table 21. Global Multivalent Influenza Vaccines Sales Market Share by Region (2027-2032) Table 22. Global Multivalent Influenza Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Multivalent Influenza Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Multivalent Influenza Vaccines Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Multivalent Influenza Vaccines Sales Market Share by Manufacturers (2021-2026) Table 26. Global Multivalent Influenza Vaccines Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Multivalent Influenza Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Multivalent Influenza Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Multivalent Influenza Vaccines Manufacturers, Product Type & Application Table 30. Global Multivalent Influenza Vaccines Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Multivalent Influenza Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Multivalent Influenza Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2026) Table 37. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2027-2032) Table 38. Global Multivalent Influenza Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 40. Global Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 41. Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2026) Table 42. Global Multivalent Influenza Vaccines Sales Market Share by Type (2027-2032) Table 43. Global Multivalent Influenza Vaccines Price by Type (2021-2026) & (US$/Unit) Table 44. Global Multivalent Influenza Vaccines Price by Type (2027-2032) & (US$/Unit) Table 45. Global Multivalent Influenza Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2026) Table 49. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2027-2032) Table 50. Global Multivalent Influenza Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 52. Global Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 53. Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2026) Table 54. Global Multivalent Influenza Vaccines Sales Market Share by Application (2027-2032) Table 55. Global Multivalent Influenza Vaccines Price by Application (2021-2026) & (US$/Unit) Table 56. Global Multivalent Influenza Vaccines Price by Application (2027-2032) & (US$/Unit) Table 57. CSL Company Information Table 58. CSL Business Overview Table 59. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. CSL Multivalent Influenza Vaccines Product Portfolio Table 61. CSL Recent Development Table 62. KM Biologics Company Information Table 63. KM Biologics Business Overview Table 64. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. KM Biologics Multivalent Influenza Vaccines Product Portfolio Table 66. KM Biologics Recent Development Table 67. Viatris Company Information Table 68. Viatris Business Overview Table 69. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Viatris Multivalent Influenza Vaccines Product Portfolio Table 71. Viatris Recent Development Table 72. AstraZeneca Company Information Table 73. AstraZeneca Business Overview Table 74. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. AstraZeneca Multivalent Influenza Vaccines Product Portfolio Table 76. AstraZeneca Recent Development Table 77. Bcht Biotechnology Company Information Table 78. Bcht Biotechnology Business Overview Table 79. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio Table 81. Bcht Biotechnology Recent Development Table 82. Sinovac Company Information Table 83. Sinovac Business Overview Table 84. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Sinovac Multivalent Influenza Vaccines Product Portfolio Table 86. Sinovac Recent Development Table 87. Aleph Biomedical Company Information Table 88. Aleph Biomedical Business Overview Table 89. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio Table 91. Aleph Biomedical Recent Development Table 92. GSK Company Information Table 93. GSK Business Overview Table 94. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. GSK Multivalent Influenza Vaccines Product Portfolio Table 96. GSK Recent Development Table 97. ADIMMUNE Corporation Company Information Table 98. ADIMMUNE Corporation Business Overview Table 99. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio Table 101. ADIMMUNE Corporation Recent Development Table 102. Hualan Bio Company Information Table 103. Hualan Bio Business Overview Table 104. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Hualan Bio Multivalent Influenza Vaccines Product Portfolio Table 106. Hualan Bio Recent Development Table 107. Jiangsu GDK Company Information Table 108. Jiangsu GDK Business Overview Table 109. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio Table 111. Jiangsu GDK Recent Development Table 112. Sanofi Company Information Table 113. Sanofi Business Overview Table 114. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Sanofi Multivalent Influenza Vaccines Product Portfolio Table 116. Sanofi Recent Development Table 117. Shanghai Institute of Biological Products Company Information Table 118. Shanghai Institute of Biological Products Business Overview Table 119. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 121. Shanghai Institute of Biological Products Recent Development Table 122. Wuhan Institute of Biological Products Company Information Table 123. Wuhan Institute of Biological Products Business Overview Table 124. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio Table 126. Wuhan Institute of Biological Products Recent Development Table 127. Changchun Institute of Biological Company Information Table 128. Changchun Institute of Biological Business Overview Table 129. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio Table 131. Changchun Institute of Biological Recent Development Table 132. Zhongyianke Biotech Company Information Table 133. Zhongyianke Biotech Business Overview Table 134. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio Table 136. Zhongyianke Biotech Recent Development Table 137. North America Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 140. North America Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 141. North America Multivalent Influenza Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 142. North America Multivalent Influenza Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 143. North America Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 144. North America Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 145. North America Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 146. North America Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 147. North America Multivalent Influenza Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 148. North America Multivalent Influenza Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 149. North America Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 151. North America Multivalent Influenza Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 152. North America Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 153. North America Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 154. North America Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 155. North America Multivalent Influenza Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 156. North America Multivalent Influenza Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 157. United States Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 158. Canada Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 159. Europe Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 160. Europe Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 161. Europe Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 162. Europe Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 163. Europe Multivalent Influenza Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 164. Europe Multivalent Influenza Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 165. Europe Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 166. Europe Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 167. Europe Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 168. Europe Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 169. Europe Multivalent Influenza Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 170. Europe Multivalent Influenza Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 171. Europe Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. Europe Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 173. Europe Multivalent Influenza Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 174. Europe Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 175. Europe Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 176. Europe Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 177. Europe Multivalent Influenza Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 178. Europe Multivalent Influenza Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 179. Germany Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 180. France Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 181. U.K. Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 182. Italy Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 183. Netherlands Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 184. China Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 185. China Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 186. China Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 187. China Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 188. China Multivalent Influenza Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 189. China Multivalent Influenza Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 190. China Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 191. China Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 192. China Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 193. China Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 194. China Multivalent Influenza Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 195. China Multivalent Influenza Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Asia Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 197. Asia Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 198. Asia Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 199. Asia Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 200. Asia Multivalent Influenza Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 201. Asia Multivalent Influenza Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 202. Asia Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 203. Asia Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 204. Asia Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 205. Asia Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 206. Asia Multivalent Influenza Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 207. Asia Multivalent Influenza Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 208. Asia Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 209. Asia Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 210. Asia Multivalent Influenza Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 211. Asia Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 212. Asia Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 213. Asia Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 214. Asia Multivalent Influenza Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 215. Asia Multivalent Influenza Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 216. Japan Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 217. South Korea Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 218. India Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 219. Australia Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 220. China Taiwan Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 221. Southeast Asia Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 222. SAMEA Multivalent Influenza Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 223. SAMEA Multivalent Influenza Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 224. SAMEA Multivalent Influenza Vaccines Sales by Type (2021-2026) & (K Units) Table 225. SAMEA Multivalent Influenza Vaccines Sales by Type (2027-2032) & (K Units) Table 226. SAMEA Multivalent Influenza Vaccines Sales Price by Type (2021-2026) & (US$/Unit) Table 227. SAMEA Multivalent Influenza Vaccines Sales Price by Type (2027-2032) & (US$/Unit) Table 228. SAMEA Multivalent Influenza Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 229. SAMEA Multivalent Influenza Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 230. SAMEA Multivalent Influenza Vaccines Sales by Application (2021-2026) & (K Units) Table 231. SAMEA Multivalent Influenza Vaccines Sales by Application (2027-2032) & (K Units) Table 232. SAMEA Multivalent Influenza Vaccines Sales Price by Application (2021-2026) & (US$/Unit) Table 233. SAMEA Multivalent Influenza Vaccines Sales Price by Application (2027-2032) & (US$/Unit) Table 234. SAMEA Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 235. SAMEA Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 236. SAMEA Multivalent Influenza Vaccines Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 237. SAMEA Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 238. SAMEA Multivalent Influenza Vaccines Sales by Country (2021-2026) & (K Units) Table 239. SAMEA Multivalent Influenza Vaccines Sales by Country (2027-2032) & (K Units) Table 240. SAMEA Multivalent Influenza Vaccines Sales Price by Country (2021-2026) & (US$/Unit) Table 241. SAMEA Multivalent Influenza Vaccines Sales Price by Country (2027-2032) & (US$/Unit) Table 242. Brazil Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 243. Argentina Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 244. Chile Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 245. Colombia Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 246. Peru Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 247. Saudi Arabia Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 248. Israel Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 249. UAE Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 250. Turkey Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 251. Iran Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 252. Egypt Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Table 253. Key Raw Materials Table 254. Raw Materials Key Suppliers Table 255. Multivalent Influenza Vaccines Distributors List Table 256. Multivalent Influenza Vaccines Customers List Table 257. Research Programs/Design for This Report Table 258. Authors List of This Report Table 259. Secondary Sources Table 260. Primary Sources List of Figures Figure 1. Multivalent Influenza Vaccines Image Figure 2. Global Multivalent Influenza Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multivalent Influenza Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Quadrivalent Inactivated Influenza Vaccine (IIV4) Image Figure 5. Trivalent Inactivated Influenza Vaccine (IIV3) Image Figure 6. Trivalent Live Attenuated Vaccine (LAIV3) Image Figure 7. Global Multivalent Influenza Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Multivalent Influenza Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 9. 6 Months to 3 Years Image Figure 10. Above 3 Years Image Figure 11. Global Multivalent Influenza Vaccines Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Multivalent Influenza Vaccines Revenue (2021-2032) & (US$ Million) Figure 13. Global Multivalent Influenza Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Multivalent Influenza Vaccines Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2021-2032) Figure 16. Global Multivalent Influenza Vaccines Sales (2021-2032) & (K Units) Figure 17. Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Multivalent Influenza Vaccines Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Multivalent Influenza Vaccines Sales YoY (2021-2032) & (K Units) Figure 20. Europe Multivalent Influenza Vaccines Sales YoY (2021-2032) & (K Units) Figure 21. China Multivalent Influenza Vaccines Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Multivalent Influenza Vaccines Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Multivalent Influenza Vaccines Sales YoY (2021-2032) & (K Units) Figure 24. Global Multivalent Influenza Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Multivalent Influenza Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Multivalent Influenza Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Multivalent Influenza Vaccines Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2032) Figure 30. Global Multivalent Influenza Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Multivalent Influenza Vaccines Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2032) Figure 33. Global Multivalent Influenza Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Multivalent Influenza Vaccines Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2032) Figure 36. Global Multivalent Influenza Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Multivalent Influenza Vaccines Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2032) Figure 39. North America Multivalent Influenza Vaccines Revenue Share by Type (2021-2032) Figure 40. North America Multivalent Influenza Vaccines Sales Share by Type (2021-2032) Figure 41. North America Multivalent Influenza Vaccines Revenue Share by Application (2021-2032) Figure 42. North America Multivalent Influenza Vaccines Sales Share by Application (2021-2032) Figure 43. North America Multivalent Influenza Vaccines Revenue Share by Country (2021-2032) Figure 44. North America Multivalent Influenza Vaccines Sales Share by Country (2021-2032) Figure 45. Europe Multivalent Influenza Vaccines Revenue Share by Type (2021-2032) Figure 46. Europe Multivalent Influenza Vaccines Sales Share by Type (2021-2032) Figure 47. Europe Multivalent Influenza Vaccines Revenue Share by Application (2021-2032) Figure 48. Europe Multivalent Influenza Vaccines Sales Share by Application (2021-2032) Figure 49. Europe Multivalent Influenza Vaccines Revenue Share by Country (2021-2032) Figure 50. Europe Multivalent Influenza Vaccines Sales Share by Country (2021-2032) Figure 51. China Multivalent Influenza Vaccines Revenue Share by Type (2021-2032) Figure 52. China Multivalent Influenza Vaccines Sales Share by Type (2021-2032) Figure 53. China Multivalent Influenza Vaccines Revenue Share by Application (2021-2032) Figure 54. China Multivalent Influenza Vaccines Sales Share by Application (2021-2032) Figure 55. Asia Multivalent Influenza Vaccines Revenue Share by Type (2021-2032) Figure 56. Asia Multivalent Influenza Vaccines Sales Share by Type (2021-2032) Figure 57. Asia Multivalent Influenza Vaccines Revenue Share by Application (2021-2032) Figure 58. Asia Multivalent Influenza Vaccines Sales Share by Application (2021-2032) Figure 59. Asia Multivalent Influenza Vaccines Revenue Share by Country (2021-2032) Figure 60. Asia Multivalent Influenza Vaccines Sales Share by Country (2021-2032) Figure 61. SAMEA Multivalent Influenza Vaccines Revenue Share by Type (2021-2032) Figure 62. SAMEA Multivalent Influenza Vaccines Sales Share by Type (2021-2032) Figure 63. SAMEA Multivalent Influenza Vaccines Revenue Share by Application (2021-2032) Figure 64. SAMEA Multivalent Influenza Vaccines Sales Share by Application (2021-2032) Figure 65. SAMEA Multivalent Influenza Vaccines Revenue Share by Country (2021-2032) Figure 66. SAMEA Multivalent Influenza Vaccines Sales Share by Country (2021-2032) Figure 67. Multivalent Influenza Vaccines Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Multivalent Influenza Vaccines Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Quadrivalent Inactivated Influenza Vaccine (IIV4)
  • Trivalent Inactivated Influenza Vaccine (IIV3)
  • Trivalent Live Attenuated Vaccine (LAIV3)
Applications
  • 6 Months to 3 Years
  • Above 3 Years
Companies covered
  • CSL
  • KM Biologics
  • Viatris
  • AstraZeneca
  • Bcht Biotechnology
  • Sinovac
  • Aleph Biomedical
  • GSK
  • ADIMMUNE Corporation
  • Hualan Bio
  • Jiangsu GDK
  • Sanofi
  • Shanghai Institute of Biological Products
  • Wuhan Institute of Biological Products
  • Changchun Institute of Biological
  • Zhongyianke Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Multivalent Influenza Vaccines Market by Type
  3. 1.2.1 Global Multivalent Influenza Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Quadrivalent Inactivated Influenza Vaccine (IIV4)
  5. 1.2.3 Trivalent Inactivated Influenza Vaccine (IIV3)
  6. 1.2.4 Trivalent Live Attenuated Vaccine (LAIV3)
  7. 1.3 Multivalent Influenza Vaccines Market by Application
  8. 1.3.1 Global Multivalent Influenza Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 6 Months to 3 Years
  10. 1.3.3 Above 3 Years
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Multivalent Influenza Vaccines Market Dynamics
  1. 2.1 Multivalent Influenza Vaccines Industry Trends
  2. 2.2 Multivalent Influenza Vaccines Industry Drivers
  3. 2.3 Multivalent Influenza Vaccines Industry Opportunities and Challenges
  4. 2.4 Multivalent Influenza Vaccines Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Multivalent Influenza Vaccines Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Multivalent Influenza Vaccines Revenue by Region
  3. 3.2.1 Global Multivalent Influenza Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Multivalent Influenza Vaccines Revenue by Region (2021-2026)
  5. 3.2.3 Global Multivalent Influenza Vaccines Revenue by Region (2027-2032)
  6. 3.2.4 Global Multivalent Influenza Vaccines Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Multivalent Influenza Vaccines Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Multivalent Influenza Vaccines Sales by Region
  9. 3.4.1 Global Multivalent Influenza Vaccines Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Multivalent Influenza Vaccines Sales by Region (2021-2026)
  11. 3.4.3 Global Multivalent Influenza Vaccines Sales by Region (2027-2032)
  12. 3.4.4 Global Multivalent Influenza Vaccines Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Multivalent Influenza Vaccines Revenue by Manufacturers
  2. 4.1.1 Global Multivalent Influenza Vaccines Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Multivalent Influenza Vaccines Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Multivalent Influenza Vaccines Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Multivalent Influenza Vaccines Sales by Manufacturers
  6. 4.2.1 Global Multivalent Influenza Vaccines Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Multivalent Influenza Vaccines Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Multivalent Influenza Vaccines Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Multivalent Influenza Vaccines Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Multivalent Influenza Vaccines Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Multivalent Influenza Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Multivalent Influenza Vaccines Manufacturers, Product Type & Application
  13. 4.7 Global Multivalent Influenza Vaccines Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Multivalent Influenza Vaccines Market CR5 and HHI
  16. 4.8.2 2025 Multivalent Influenza Vaccines Tier 1, Tier 2, and Tier 3
5 Multivalent Influenza Vaccines Market by Type
  1. 5.1 Global Multivalent Influenza Vaccines Revenue by Type
  2. 5.1.1 Global Multivalent Influenza Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Multivalent Influenza Vaccines Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Multivalent Influenza Vaccines Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Multivalent Influenza Vaccines Sales by Type
  6. 5.2.1 Global Multivalent Influenza Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Multivalent Influenza Vaccines Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Multivalent Influenza Vaccines Sales Market Share by Type (2021-2032)
  9. 5.3 Global Multivalent Influenza Vaccines Price by Type
6 Multivalent Influenza Vaccines Market by Application
  1. 6.1 Global Multivalent Influenza Vaccines Revenue by Application
  2. 6.1.1 Global Multivalent Influenza Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Multivalent Influenza Vaccines Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Multivalent Influenza Vaccines Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Multivalent Influenza Vaccines Sales by Application
  6. 6.2.1 Global Multivalent Influenza Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Multivalent Influenza Vaccines Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Multivalent Influenza Vaccines Sales Market Share by Application (2021-2032)
  9. 6.3 Global Multivalent Influenza Vaccines Price by Application
7 Company Profiles
  1. 7.1 CSL
  2. 7.1.1 CSL Company Information
  3. 7.1.2 CSL Business Overview
  4. 7.1.3 CSL Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 CSL Multivalent Influenza Vaccines Product Portfolio
  6. 7.1.5 CSL Recent Developments
  7. 7.2 KM Biologics
  8. 7.2.1 KM Biologics Company Information
  9. 7.2.2 KM Biologics Business Overview
  10. 7.2.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
  12. 7.2.5 KM Biologics Recent Developments
  13. 7.3 Viatris
  14. 7.3.1 Viatris Company Information
  15. 7.3.2 Viatris Business Overview
  16. 7.3.3 Viatris Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Viatris Multivalent Influenza Vaccines Product Portfolio
  18. 7.3.5 Viatris Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 Bcht Biotechnology
  26. 7.5.1 Bcht Biotechnology Company Information
  27. 7.5.2 Bcht Biotechnology Business Overview
  28. 7.5.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
  30. 7.5.5 Bcht Biotechnology Recent Developments
  31. 7.6 Sinovac
  32. 7.6.1 Sinovac Company Information
  33. 7.6.2 Sinovac Business Overview
  34. 7.6.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
  36. 7.6.5 Sinovac Recent Developments
  37. 7.7 Aleph Biomedical
  38. 7.7.1 Aleph Biomedical Company Information
  39. 7.7.2 Aleph Biomedical Business Overview
  40. 7.7.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
  42. 7.7.5 Aleph Biomedical Recent Developments
  43. 7.8 GSK
  44. 7.8.1 GSK Company Information
  45. 7.8.2 GSK Business Overview
  46. 7.8.3 GSK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GSK Multivalent Influenza Vaccines Product Portfolio
  48. 7.8.5 GSK Recent Developments
  49. 7.9 ADIMMUNE Corporation
  50. 7.9.1 ADIMMUNE Corporation Company Information
  51. 7.9.2 ADIMMUNE Corporation Business Overview
  52. 7.9.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
  54. 7.9.5 ADIMMUNE Corporation Recent Developments
  55. 7.10 Hualan Bio
  56. 7.10.1 Hualan Bio Company Information
  57. 7.10.2 Hualan Bio Business Overview
  58. 7.10.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
  60. 7.10.5 Hualan Bio Recent Developments
  61. 7.11 Jiangsu GDK
  62. 7.11.1 Jiangsu GDK Company Information
  63. 7.11.2 Jiangsu GDK Business Overview
  64. 7.11.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
  66. 7.11.5 Jiangsu GDK Recent Developments
  67. 7.12 Sanofi
  68. 7.12.1 Sanofi Company Information
  69. 7.12.2 Sanofi Business Overview
  70. 7.12.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
  72. 7.12.5 Sanofi Recent Developments
  73. 7.13 Shanghai Institute of Biological Products
  74. 7.13.1 Shanghai Institute of Biological Products Company Information
  75. 7.13.2 Shanghai Institute of Biological Products Business Overview
  76. 7.13.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  78. 7.13.5 Shanghai Institute of Biological Products Recent Developments
  79. 7.14 Wuhan Institute of Biological Products
  80. 7.14.1 Wuhan Institute of Biological Products Company Information
  81. 7.14.2 Wuhan Institute of Biological Products Business Overview
  82. 7.14.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
  84. 7.14.5 Wuhan Institute of Biological Products Recent Developments
  85. 7.15 Changchun Institute of Biological
  86. 7.15.1 Changchun Institute of Biological Company Information
  87. 7.15.2 Changchun Institute of Biological Business Overview
  88. 7.15.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
  90. 7.15.5 Changchun Institute of Biological Recent Developments
  91. 7.16 Zhongyianke Biotech
  92. 7.16.1 Zhongyianke Biotech Company Information
  93. 7.16.2 Zhongyianke Biotech Business Overview
  94. 7.16.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
  96. 7.16.5 Zhongyianke Biotech Recent Developments
8 North America
  1. 8.1 North America Multivalent Influenza Vaccines Market Size by Type
  2. 8.1.1 North America Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  3. 8.1.2 North America Multivalent Influenza Vaccines Sales by Type (2021-2032)
  4. 8.1.3 North America Multivalent Influenza Vaccines Price by Type (2021-2032)
  5. 8.2 North America Multivalent Influenza Vaccines Market Size by Application
  6. 8.2.1 North America Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  7. 8.2.2 North America Multivalent Influenza Vaccines Sales by Application (2021-2032)
  8. 8.2.3 North America Multivalent Influenza Vaccines Price by Application (2021-2032)
  9. 8.3 North America Multivalent Influenza Vaccines Market Size by Country
  10. 8.3.1 North America Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Multivalent Influenza Vaccines Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Multivalent Influenza Vaccines Market Size by Type
  2. 9.1.1 Europe Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  3. 9.1.2 Europe Multivalent Influenza Vaccines Sales by Type (2021-2032)
  4. 9.1.3 Europe Multivalent Influenza Vaccines Price by Type (2021-2032)
  5. 9.2 Europe Multivalent Influenza Vaccines Market Size by Application
  6. 9.2.1 Europe Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  7. 9.2.2 Europe Multivalent Influenza Vaccines Sales by Application (2021-2032)
  8. 9.2.3 Europe Multivalent Influenza Vaccines Price by Application (2021-2032)
  9. 9.3 Europe Multivalent Influenza Vaccines Market Size by Country
  10. 9.3.1 Europe Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Multivalent Influenza Vaccines Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Multivalent Influenza Vaccines Market Size by Type
  2. 10.1.1 China Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  3. 10.1.2 China Multivalent Influenza Vaccines Sales by Type (2021-2032)
  4. 10.1.3 China Multivalent Influenza Vaccines Price by Type (2021-2032)
  5. 10.2 China Multivalent Influenza Vaccines Market Size by Application
  6. 10.2.1 China Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  7. 10.2.2 China Multivalent Influenza Vaccines Sales by Application (2021-2032)
  8. 10.2.3 China Multivalent Influenza Vaccines Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Multivalent Influenza Vaccines Market Size by Type
  2. 11.1.1 Asia Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  3. 11.1.2 Asia Multivalent Influenza Vaccines Sales by Type (2021-2032)
  4. 11.1.3 Asia Multivalent Influenza Vaccines Price by Type (2021-2032)
  5. 11.2 Asia Multivalent Influenza Vaccines Market Size by Application
  6. 11.2.1 Asia Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  7. 11.2.2 Asia Multivalent Influenza Vaccines Sales by Application (2021-2032)
  8. 11.2.3 Asia Multivalent Influenza Vaccines Price by Application (2021-2032)
  9. 11.3 Asia Multivalent Influenza Vaccines Market Size by Country
  10. 11.3.1 Asia Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Multivalent Influenza Vaccines Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Multivalent Influenza Vaccines Market Size by Type
  2. 12.1.1 SAMEA Multivalent Influenza Vaccines Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Multivalent Influenza Vaccines Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Multivalent Influenza Vaccines Price by Type (2021-2032)
  5. 12.2 SAMEA Multivalent Influenza Vaccines Market Size by Application
  6. 12.2.1 SAMEA Multivalent Influenza Vaccines Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Multivalent Influenza Vaccines Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Multivalent Influenza Vaccines Price by Application (2021-2032)
  9. 12.3 SAMEA Multivalent Influenza Vaccines Market Size by Country
  10. 12.3.1 SAMEA Multivalent Influenza Vaccines Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Multivalent Influenza Vaccines Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Multivalent Influenza Vaccines Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Multivalent Influenza Vaccines Value Chain Analysis
  2. 13.1.1 Multivalent Influenza Vaccines Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Multivalent Influenza Vaccines Production Mode & Process
  6. 13.2 Multivalent Influenza Vaccines Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Multivalent Influenza Vaccines Distributors
  9. 13.2.3 Multivalent Influenza Vaccines Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst